ReviewAnnals of intensive care2020
Vasopressin and its analogues in shock states: a review.
Review in Annals of intensive care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06422975 (Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care Units), which is not on this map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care Units
Who cites it
62 citing papers in PubMed, 122 citations in OpenAlex.
- Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study.Renal failure · 2022Trial
- Effect of vasopressin and its analogues on microcirculatory perfusion: a systematic review.Intensive care medicine experimental · 2026Review
- Endocrine Effects of Arginine-Vasopressin After Pediatric Cardiac Surgery.Pediatric cardiology · 2026Article
- Use of Natriuretic Peptides in Critically Ill Patients: A Narrative Review.Journal of clinical medicine · 2026Review
- Early combination of terlipressin and norepinephrine in the treatment of patients with septic shock.Clinics (Sao Paulo, Brazil) · 2026Article
- Modulation of the Vasopressin System in Distributive and Cardiogenic Shock: Theoretical Principles and Practical Applications.Journal of clinical medicine · 2026Review
- Perioperative Vasopressor Management in Noncardiac Surgical Patients.Anesthesiology · 2026Article
- Revisiting the need for innovative oral hydration technologies.Frontiers in nutrition · 2026Review
- Endogenous mediators in regulating primary dysmenorrhea.Frontiers in cell and developmental biology · 2026Review
- IgE and non-IgE-mediated pathways in anaphylaxis.Seminars in immunopathology · 2025Review
- Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?Critical care (London, England) · 2025Review
- Vasopressin use across shock states: international insights from an international ESICM-endorsed survey: the PRESS Survey.Critical care (London, England) · 2025Article
- Comparison between norepinephrine plus epinephrine and norepinephrine plus vasopressin after return of spontaneous circulation in patients with out-of-hospital cardiac arrest.Scientific reports · 2025Observational
- Vasopressin: a review of clinical indications.Clinical and experimental emergency medicine · 2025Article
- Oxytocin in horse saliva: validation of a highly sensitive assay and a pilot report about changes in equine gastric ulcer syndrome.BMC veterinary research · 2025Article
- Individualized drug therapy and survival prediction in ICU patients with acute kidney injury: construction and validation of a nomogram.European journal of medical research · 2025Article
- Acute Kidney Injury During Sepsis and Prognostic Role of Coexistent Chronic Heart Failure.Journal of clinical medicine · 2025Review
- Analysis of the correlation between the group-based trajectory modeling of serum osmolality and prognosis in patients with sepsis-associated encephalopathy at 72 h after admission.BMC infectious diseases · 2025Article
- Beyond the heart: a review exploring non-cardiovascular effects of vasoactive agents.Frontiers in pharmacology · 2025Review
- The Effect of Vasopressin on 90-Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score-Weighted Analysis.Cardiovascular therapeutics · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of arginine-vasopressin is one of the hormonal responses to face vasodilation-related hypotension. Released from the post-pituitary gland, vasopressin induces vasoconstriction through the activation of V1a receptors located on vascular smooth muscle cells. Due to its non-selective receptor affinity arginine-vasopressin also activates V2 (located on renal tubular cells of collecting ducts) and V1b (located in the anterior pituitary and in the pancreas) receptors, thereby potentially promoting undesired side effects such as anti-diuresis, procoagulant properties due to release of the von Willebrand's factor and platelet activation. Finally, it also cross-activates oxytocin receptors. During septic shock, vasopressin plasma levels were reported to be lower than expected, and a hypersensitivity to its vasopressor effect is reported in such situation. Terlipressin and selepressin are synthetic vasopressin analogues with a higher affinity for the V1 receptor, and, hence, potentially less side effects. In this narrative review, we present the current knowledge of the rationale, benefits and risks of vasopressin use in the setting of septic shock and vasoplegic shock following cardiac surgery. Clearly, vasopressin administration allows reducing norepinephrine requirements, but so far, no improvement of survival was reported and side effects are frequent, particularly ischaemic events. Finally, we will discuss the current indications for vasopressin and its agonists in the setting of septic shock, and the remaining unresolved questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.